We're lowering our price target on Bristol Myers as two key overhangs persist

Bristol Myers Squibb shares dropped 4% despite reporting a solid Q2 earnings beat ($12.3 billion revenue, $1.46 adjusted EPS) and raising full-year guidance. The decline is primarily attributed to investor uncertainty surrounding the growth trajectory of the recently acquired schizophrenia drug Cobenfy, particularly ahead of critical late-stage trial data for Alzheimer's psychosis patients, following a prior failed Phase 3 trial. Despite management's reassurance regarding Cobenfy's launch, the market views the stock as a 'value trap' until this data clarifies the drug's potential, leading to a price target cut and a 'hold' rating, with additional headwinds from potential Trump administration pharmaceutical policy proposals.

Analysis

Bristol Myers Squibb presents a clear disconnect between strong current operational performance and negative forward-looking market sentiment. The company reported a significant second-quarter beat, with revenue of $12.3 billion surpassing estimates of $11.4 billion and adjusted EPS of $1.46 exceeding the $1.07 consensus. Furthermore, management raised full-year sales guidance to a range of $46.5 billion to $47.5 billion, citing strength in its growth portfolio and a slower decline in legacy products like Revlimid. The adjusted EPS guidance of $6.35 to $6.65, while nominally lower, represents an underlying raise when excluding a 57-cent per share IPRD charge from its BioNTech partnership. Despite these positive fundamentals, the stock fell 4% as investor focus remains fixated on the uncertain future of Cobenfy, a key schizophrenia treatment acquired through the $14 billion Karuna Therapeutics deal. Confidence in the drug's potential has been undermined by a previously failed Phase 3 trial, making the upcoming late-stage data for Alzheimer's psychosis a pivotal, make-or-break catalyst. This single clinical event is creating an overhang that overshadows the entire investment case, leading to the stock being characterized as a potential 'value trap' despite its low valuation of less than 7 times forward earnings and a nearly 6% dividend yield. Compounding this uncertainty is a sector-wide headwind from potential new pharmaceutical pricing policies from a Trump administration.

Key Decisions for Investors

• Investors must weigh the company's solid Q2 performance and upwardly revised guidance against the significant binary risk presented by the upcoming late-stage trial data for Cobenfy in Alzheimer's psychosis.
• Despite a compelling valuation at less than 7x forward EPS and a high dividend yield of nearly 6%, the stock is likely to remain a 'value trap' until the Cobenfy clinical trial results are released, suggesting caution against initiating or adding to positions.
• The attractive dividend may compensate existing shareholders for waiting through the period of uncertainty, but the primary catalyst for a re-rating of the stock is wholly dependent on positive clinical news.
• Monitor for external political developments, as proposed 'most favored nation' drug pricing policies represent a material sector-wide risk that could further pressure the stock irrespective of company-specific results.